US legislation seeks to give generics labelling change abilities
This article was originally published in SRA
Executive Summary
If legislation introduced this week in the US House and Senate is enacted, generic drug makers would have the ability to update the labelling of their products with new safety information without having to wait for the firm that markets the referenced brand-name medicine to take such action1,2.